Sanofi SA
SNW
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
74,846
Stocks News & Analysis
stocks
A closer look at US tech earnings
How a handful of tech giants continue to shape market returns and what investors should watch next.
stocks
Cheap ASX energy share lifts earnings guidance on stronger output
Energy provider lifts earnings guidance on stronger power plant performance.
stocks
ASX listed bank overvalued despite strong earnings
Profit beats drive shares higher for Australia’s largest asset manager.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,909.60 | 42.50 | -0.47% |
| CAC 40 | 8,007.20 | 49.18 | -0.61% |
| DAX 40 | 24,092.09 | 258.19 | -1.06% |
| Dow JONES (US) | 49,704.47 | 95.31 | 0.19% |
| FTSE 100 | 10,229.41 | 40.02 | -0.39% |
| HKSE | 26,347.91 | 58.93 | -0.22% |
| NASDAQ | 26,274.13 | 27.05 | 0.10% |
| Nikkei 225 | 62,742.57 | 324.69 | 0.52% |
| NZX 50 Index | 13,080.33 | 130.15 | -0.99% |
| S&P 500 | 7,412.84 | 13.91 | 0.19% |
| S&P/ASX 200 | 8,670.70 | 40.60 | -0.47% |
| SSE Composite Index | 4,214.49 | 10.53 | -0.25% |